0000000000811761

AUTHOR

Massimo Bellavia

showing 1 related works from this author

Treatment Monitoring Program for Implementation of Adherence to Second-Line Erlotinib for Advanced Non–Small-Cell Lung Cancer

2012

Abstract Background Adherence to erlotinib could be a determinant for clinical outcome and treatment toxicity in patients with advanced non–small-cell lung cancer (A-NSCLC). Patients and Methods In an observational study, the Basel Assessment of Adherence Scale (BAAS), a visual analogue scale (VAS), pill counting, and missed appointment rate were used to evaluate adherence in a first cohort of patients who was prescribed erlotinib without a specifically designed management strategy and in a second cohort of patients followed by an oral treatment monitoring program. Results Adherence > 95% by BAAS at 2 months of treatment in the first and second cohorts was 72% and 84%, respectively ( P = .0…

AdultMalePulmonary and Respiratory MedicineCancer Researchmedicine.medical_specialtyLung NeoplasmsVisual analogue scaleAdenocarcinomaMedication AdherenceErlotinib HydrochlorideCarcinoma Non-Small-Cell LungInternal medicinemedicineHumansErlotinib HydrochlorideProtein Kinase InhibitorsSurvival rateAgedNeoplasm StagingRetrospective StudiesAged 80 and overSalvage Therapybusiness.industryHealth Plan ImplementationRetrospective cohort studyAdenocarcinoma Bronchiolo-AlveolarMiddle AgedPrognosisSmall Cell Lung CarcinomaMonitoring programConfidence intervalSurgerySurvival RateOncologyCohortQuinazolinesCarcinoma Large CellPatient ComplianceFemaleErlotinibDrug MonitoringbusinessFollow-Up Studiesmedicine.drugClinical Lung Cancer
researchProduct